You’ve been tasked with planning a great (and productive!) meeting for over 1,000 attendees. Feeling anxious yet? No need—Vegas has the perfect event spaces to accommodate extra-large groups. Here’s how to get all of those people talking about your business with the backdrop of an incredible venue, of course. Caesars Palace
Immune Checkpoint Inhibitors 2017
Event contact title
Event contact first name
Event contact last name
Event contact telephone number
1 212 537 5898 / +44 (0) 20 3141 8700
Returning for the third year, ICI Boston 2017 is the only conference that focuses exclusively on delivering maximum clinical benefit through immune checkpoint monotherapy and combinations, from pathway validation to clinical success. Gain in-depth insights from Merck, BMS, Genentech, MedImmune, Novartis and EMD Serono and transform the success of your immuno-oncology approach. Rather than replicating broad immuno-oncology conferences, the narrow focus of this immune checkpoint meeting enables an unprecedented depth of content. Deliver robust and durable responses through rational combinations, examine next generation biomarker approaches to successfully stratify patients for clinical success and learn about checkpoint pathways beyond T cells to maximize the holistic anti-tumor response.
ICI Boston will enable you to: - Deliver robust and durable responses by gaining insights into rational immuno-oncology combination strategies - Differentiate yourself from the competition by understanding the true potential of the next generation of immunotherapies, including pioneering GITR, ICOS, VISTA and CD47 programs - Boost the response rate to checkpoint modulation by understanding the promise of oncolytic virotherapy, chemotherapy and radiotherapy in kick-starting anti-tumor immune responses - Enhance patient stratification by dissecting the utility of PD-L1 expression as a biomarker and examining the next generation of immune signature approaches - Ensure Commercial Success by examining how commercial partnerships and collaborations can be optimized and market share maximized in this rapidly evolving space - Bolster the holistic anti-tumour immune response by learning about the integral role NK cells, macrophages, Tregs, dendritic cells and many other cell types play.